采纳股份跌1.25%，成交额4813.76万元，近3日主力净流入-741.67万

Core Viewpoint - The company, Canar Medical, is experiencing a decline in stock price and revenue, while benefiting from the depreciation of the RMB due to its significant overseas revenue. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][8] - The company began supplying IVF culture tube products to Thermo Fisher in 2018 [3] - As of September 19, the number of shareholders in Canar Medical is 6,901, a decrease of 11.17% from the previous period, while the average circulating shares per person increased by 12.58% [8] Group 2: Financial Performance - For the first half of 2025, Canar Medical reported revenue of 158 million yuan, a year-on-year decrease of 18.54%, and a net profit attributable to shareholders of 9.37 million yuan, down 71.78% year-on-year [8] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed in the last three years [9] Group 3: Market Dynamics - The stock price of Canar Medical fell by 1.25% on September 26, with a trading volume of 48.14 million yuan and a turnover rate of 2.60%, bringing the total market value to 2.99 billion yuan [1] - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [4] Group 4: Technical Analysis - The average trading cost of the stock is 23.47 yuan, with recent rapid outflows of shares, suggesting a recommendation for portfolio adjustment [7] - The current stock price is approaching a resistance level of 24.88 yuan, indicating potential for a pullback unless this level is broken [7]